Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Heberprot-P: a novel product for treating advanced diabetic foot ulcer.
Berlanga J, Fernández JI, López E, López PA, del Río A, Valenzuela C, Baldomero J, Muzio V, Raíces M, Silva R, Acevedo BE, Herrera L. Berlanga J, et al. Among authors: herrera l. MEDICC Rev. 2013 Jan;15(1):11-5. doi: 10.37757/MR2013V15.N1.4. MEDICC Rev. 2013. PMID: 23396236 Free article.
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: herrera l. Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25. Mol Cell Biochem. 2008. PMID: 18575815 Clinical Trial.
Ubiquitous expression of human SCA2 gene under the regulation of the SCA2 self promoter cause specific Purkinje cell degeneration in transgenic mice.
Aguiar J, Fernández J, Aguilar A, Mendoza Y, Vázquez M, Suárez J, Berlanga J, Cruz S, Guillén G, Herrera L, Velázquez L, Santos N, Merino N. Aguiar J, et al. Among authors: herrera l. Neurosci Lett. 2006 Jan 16;392(3):202-6. doi: 10.1016/j.neulet.2005.09.020. Epub 2005 Oct 3. Neurosci Lett. 2006. PMID: 16203087
Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.
Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P. Solares AM, et al. Among authors: herrera l. BMC Cancer. 2009 May 13;9:146. doi: 10.1186/1471-2407-9-146. BMC Cancer. 2009. PMID: 19439079 Free PMC article. Clinical Trial.
Proteomic study via a non-gel based approach of meningococcal outer membrane vesicle vaccine obtained from strain CU385: a road map for discovering new antigens.
Gil J, Betancourt LZ, Sardiñas G, Yero D, Niebla O, Delgado M, García D, Pajón R, Sánchez A, González LJ, Padrón G, Campa C, Sotolongo F, Barberó R, Guillén G, Herrera L, Besada V. Gil J, et al. Among authors: herrera l. Hum Vaccin. 2009 May;5(5):347-56. doi: 10.4161/hv.5.5.7367. Epub 2009 May 8. Hum Vaccin. 2009. PMID: 19377283
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: herrera l. Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7. Mol Cell Biochem. 2011. PMID: 21735096 Clinical Trial.
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.
Junco JA, Rodríguez R, Fuentes F, Baladrón I, Castro MD, Calzada L, Valenzuela C, Bover E, Pimentel E, Basulto R, Arteaga N, Cid-Arregui A, Sariol F, González L, Porres-Fong L, Medina M, Rodríguez A, Garay AH, Reyes O, López M, de Quesada L, Alvarez A, Martínez C, Marrero M, Molero G, Guerra A, Rosales P, Capote C, Acosta S, Vela I, Arzuaga L, Campal A, Ruiz E, Rubio E, Cedeño P, Sánchez MC, Cardoso P, Morán R, Fernández Y, Campos M, Touduri H, Bacardi D, Feria I, Ramirez A, Cosme K, Saura PL, Quintana M, Muzio V, Bringas R, Ayala M, Mendoza M, Fernández LE, Carr A, Herrera L, Guillén G. Junco JA, et al. Among authors: herrera l. Front Oncol. 2019 Feb 25;9:49. doi: 10.3389/fonc.2019.00049. eCollection 2019. Front Oncol. 2019. PMID: 30859088 Free PMC article.
Taking stock of Cuban biotech.
López E, Silva R, Acevedo B, Buxadó JA, Aguilera A, Herrera L. López E, et al. Among authors: herrera l. Nat Biotechnol. 2007 Nov;25(11):1215-6. doi: 10.1038/nbt1107-1215. Nat Biotechnol. 2007. PMID: 17989669 No abstract available.
Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination.
Castellanos M, Cinza Z, Dorta Z, Veliz G, Vega H, Lorenzo I, Ojeda S, Dueñas-Carrera S, Alvarez-Lajonchere L, Martínez G, Ferrer E, Limonta M, Linares M, Ruiz O, Acevedo B, Torres D, Márquez G, Herrera L, Arús E. Castellanos M, et al. Among authors: herrera l. J Gene Med. 2010 Jan;12(1):107-16. doi: 10.1002/jgm.1407. J Gene Med. 2010. PMID: 19866482 Clinical Trial.
862 results